Tuberculin
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- Tuberculin
- tuberculin
- Tuberculin
- tuberculin old
- tuberculin ppd
- Tuberculin ppd
- tuberculin purified protein derivative of
- Tuberculin, old
- Tuberculin, purified protein derivative of
- tuberculinum
- Tuberculinum
- ATC classification codes
- V04CF01
Sources for recorded values
- ChEMBL ID
- CHEMBL2108161
- RxNorm IDs (RxCUI)
- 10908
- First in class
- No
- Orphan designation
- No
- Condition
- Condylomata Acuminata
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007147
- Subject identifier
- D003218
- Condition
- Warts
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009662
- Subject identifier
- D014860
- Condition
- Tuberculosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0018076
- Subject identifier
- D014376
- Condition identifier
- EFO_0007147
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009429
- Condition identifier
- EFO_0009429
- Highest recorded phase
- 4
- Condition identifier
- EFO_0009662
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001209
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005647
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018076
- Event
- erythema
- Reports
- 10
- Reporting signal score
- 17.0982
- Event
- extensive swelling of vaccinated limb
- Reports
- 3
- Reporting signal score
- 27.6455
- Event
- induration
- Reports
- 4
- Reporting signal score
- 20.0344
- Event
- injection site desquamation
- Reports
- 1
- Reporting signal score
- 7.65215
- Event
- injection site erythema
- Reports
- 10
- Reporting signal score
- 18.3196
- Event
- injection site pruritus
- Reports
- 5
- Reporting signal score
- 8.76885
- Event
- injection site vesicles
- Reports
- 2
- Reporting signal score
- 7.08648
- Event
- pruritus
- Reports
- 11
- Reporting signal score
- 14.8936
- Event
- radiation exposure during pregnancy
- Reports
- 1
- Reporting signal score
- 9.35676
- Event
- skin irritation
- Reports
- 4
- Reporting signal score
- 13.8076
- Event
- skin warm
- Reports
- 2
- Reporting signal score
- 7.15894
- Event
- throat tightness
- Reports
- 4
- Reporting signal score
- 10.0175
- Event
- tuberculin test
- Reports
- 1
- Reporting signal score
- 7.05525
- Event
- tuberculin test negative
- Reports
- 1
- Reporting signal score
- 8.66364
- Event
- tuberculin test positive
- Reports
- 2
- Reporting signal score
- 7.5295
- Event
- tuberculosis
- Reports
- 3
- Reporting signal score
- 7.95299
- Event
- urticaria
- Reports
- 9
- Reporting signal score
- 13.6172
- Event
- vaccination error
- Reports
- 1
- Reporting signal score
- 7.41183
- Event
- vaccination site erythema
- Reports
- 3
- Reporting signal score
- 22.1312
- Event
- vaccination site inflammation
- Reports
- 2
- Reporting signal score
- 16.3689
- Event
- vaccination site pain
- Reports
- 3
- Reporting signal score
- 21.7478
- Event
- vaccination site reaction
- Reports
- 2
- Reporting signal score
- 16.7029
- Event
- vaccination site ulcer
- Reports
- 1
- Reporting signal score
- 8.66364
- Event
- vaccination site warmth
- Reports
- 1
- Reporting signal score
- 7.27833
- Event
- wrong product administered
- Reports
- 8
- Reporting signal score
- 40.9541
- NCT03153566
- NCT04288817
- NCT05027958
- NCT05899179
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (19)
- Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
- Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
- Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children
- Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
- Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
- Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients
- Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
- Efficacy of Cryotherapy Combined With Intralesional Tuberculin PPD Versus Intralesional Tuberculin PPD in Treatment of Multiple Common Warts
- Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)
- Impact Of Intralesional Tuberculin Ppd Injection On Anogenital
- Investigating Immune Mechanisms in Atopic Eczema
- Leprosy Skin Test Antigens Trial
- Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections
- Phase II Clinical Clical of the Pure Protein Derivatives of BCG
- Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
- The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
- Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)
- Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection
- Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers
In development for (3)
- Anogenital human papillomavirus infection Phase 3
- Common wart Phase 3
- Tuberculosis Phase 3